A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-26. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Glutamic acid decarboxylase autoantibodies (GADA), islet cell autoantibodies (ICA), insulinoma-associated (IA-2) autoantibodies, and zinc transporter autoantibodies (ZnT8) are all associated with LADA; GADAs are commonly found in cases of diabetes mellitus type 1. The presence of islet cell complement fixing autoantibodies also aids in a differential diagnosis between LADA and type 2 diabetes. Persons with LADA often test positive for ICA, whereas type 2 diabetics only seldom do. Persons with LADA usually test positive for glutamic acid decarboxylase antibodies, whereas in type 1 diabetes these antibodies are more commonly seen in adults rather than in children. In addition to being useful in making an early diagnosis for type 1 diabetes mellitus, GAD antibodies tests are used for differential diagnosis between LADA and type 2 diabetes and may also be used for differential diagnosis of gestational diabetes, risk prediction in immediate family members for type 1, as well as a tool to monitor prognosis of the clinical progression of type 1 diabetes.
The most significant doping scandal in AFL history surrounded the Essendon Football Club and the sports supplements program it ran in the lead-up to and during the 2012 season. Following a long investigation, which began with the club's self-reporting in February 2013, thirty-four Essendon players were found guilty in January 2016 by the Court of Arbitration for Sport of using the banned substance Thymosin beta-4, each receiving a partially backdated two-year suspension which will result in all missing the 2016 AFL season – the decision was subsequently appealed, and was eventually dismissed, by the Federal Supreme Court of Switzerland. The club faced severe penalties in August 2013 for the poor governance in which the program was run including its lack of documentation and its questionable hiring practices – guilt related to administering a banned substance had not been established at this point – and the club was penalised with a $2 million fine, a loss of high draft picks in the following two drafts, being omitted from the 2013 AFL Finals Series despite finishing seventh on the ladder, and suspensions to key personnel including senior coach James Hird.
== Risks == Solid evidence is hard to obtain, as these substances come from many different environments cross-culturally and therefore give variable results, because of variations in growth and extraction. The same is also true for unnatural substances, because variations in consumption and individual sensitivity can affect outcomes. Folk medicine and self-prescribed methods can be potentially harmful, as their adverse effects are not fully known and are therefore not made aware to the people searching this topic on the internet.
== History == Einstein Bros. was created by the chain restaurant corporation Boston Chicken (now Boston Market) in 1995, as a way to market breakfast foods. The chain is now owned by Panera Brands. Boston Chicken, Inc. originally formed the Einstein and Noah Bagel Corporation as Progressive Bagel Concepts, Incorporated (PBCI) in March 1995, when it purchased four retail bagel chains, all located in regions of the United States that did not have longstanding bagel traditions. These companies included Offerdahl's Bagel Gourmet (Fort Lauderdale), Bagel & Bagel (Kansas City), Baltimore Bagel (San Diego), and Brackman Brothers, Incorporated (Salt Lake City). Each found that their stores were similar in that they offered both original and new bagel flavors in wealthy neighborhoods where the customers had relatively little previous exposure to bagels. Noah's Bagels was founded in 1989 by Noah Alper on College Avenue in Berkeley, California. In 1996, the chain of 38 stores was sold to Einstein Bros. for $100 million.
== Plot summary == The novel begins with a brief prologue describing the bioforms—dubbed the First-Born—who created the black monoliths. They evolved from "primordial soup", and over the course of millions of years became a space-faring species. Perceiving that nothing was more precious than the mind, they catalysed the evolution of intelligent species wherever they went, by increasing the intelligent species' chance of survival. After visiting Earth, the First-Born found a way to impress themselves into the fabric of space and time, becoming effectively immortal. Meanwhile, the monoliths—implied to have been forgotten by their creators when they ascended to a higher state of being—continued to watch over their subjects. 3001 follows the adventures of Frank Poole, the astronaut killed by the HAL 9000 computer in 2001: A Space Odyssey. One millennium later, Poole's freeze-dried body is discovered floating in the Kuiper belt by a comet-collecting space tug named the Goliath, and revived. The resurrected Poole is taken home to learn about the Earth in the year 3001. Some of its notable features include the BrainCap, a brain–computer interface technology; genetically engineered dinosaur servants; and four gigantic space elevators located evenly around the Equator. Humans have also colonised the Jovian moons Ganymede and Callisto. TMA-1, the black monolith found on the Moon in 1999, had been brought to Earth in 2006 and installed in front of the United Nations Building in New York City.
Sources: en.wikipedia.org
The energy released by reactions of oxygen and reduced compounds such as cytochrome c and (indirectly) NADH and FADH2 is used by the electron transport chain to pump protons into the intermembrane space, generating the electrochemical gradient over the inner mitochondrial membrane. In photosynthetic eukaryotes, the electron transport chain is found on the thylakoid membrane. Here, light energy drives electron transport through a proton pump and the resulting proton gradient causes subsequent synthesis of ATP. In bacteria, the electron transport chain can vary between species but it always constitutes a set of redox reactions that are coupled to the synthesis of ATP through the generation of an electrochemical gradient and oxidative phosphorylation through ATP synthase.
==== Deficit in spatial learning ==== In 1998, Giese and colleagues studied knockout mice that have been genetically engineered to prevent CaMKII autophosphorylation. They observed that mice had trouble finding the hidden platform in the Morris water maze task. The Morris water maze task is often used to represent hippocampus-dependent spatial learning. The mice's inability to find the hidden platform implies deficits in spatial learning. However, these results were not entirely conclusive because memory formation deficit could also be associated with sensory motor impairment resulting from genetic alteration.
Visual signals where light goes more or less directly from the source to the human eye, to convey a message or meaning Illumination where light is reflected from objects to give visual response of these objects Measuring and interacting with processes involving no human vision Narrow band light sensors where LEDs operate in a reverse-bias mode and respond to incident light, instead of emitting light Indoor cultivation, including cannabis. The application of LEDs in horticulture has revolutionized plant cultivation by providing energy-efficient, customizable lighting solutions that optimize plant growth and development. LEDs offer precise control over light spectra, intensity, and photoperiods, enabling growers to tailor lighting conditions to the specific needs of different plant species and growth stages. This technology enhances photosynthesis, improves crop yields, and reduces energy costs compared to traditional lighting systems. Additionally, LEDs generate less heat, allowing closer placement to plants without risking thermal damage, and contribute to sustainable farming practices by lowering carbon footprints and extending growing seasons in controlled environments. Light spectrum affects growth, metabolite profile, and resistance against fungal phytopathogens of Solanum lycopersicum seedlings. LEDs can also be used in micropropagation.
Lately Chair, Cwm Taf Morgannwg University Health Board. For services to the NHS and Mental Health Services in Wales. Gregory Elliot. Senior Officer, National Crime Agency. For services to Law Enforcement. Stuart John Ensor. National Chair, Royal Air Force Air Cadets. For voluntary service to Young People. John Neil Everitt. Chief Executive Officer, National Forest Company. For services to Conservation. David Farnsworth. Managing Director, City Bridge Foundation. For services to the Voluntary Sector in London. Dr. Oliver Robert Ford Davies. Actor. For services to Drama. Professor David Foskett, MBE. Lately Head of Hospitality, University of West London. For services to the Hospitality Industry and to Inclusivity. Mischa Kate Foxell. Deputy Director, Cabinet Office. For Public Service. Travis Dylan Frain. Campaigner. For services to Counter Extremism and to Victims of Terrorism. Janie Lorraine Frampton. For services to Equality for Women in Sport in the UK and Abroad. Rachel Gaisburgh-Watkyn. Managing Director, Tiny Box Company. For services to Sustainability, to Ethical Business Growth and to Exports. Anthony Gallagher. Chair, National Youth Sector Advisory Board. For services to Young People. Katie Gallagher. Director, Manchester Digital. For services to the Digital Technology Industry in the North-West. Mark Robert Timothy Garnier, MP. Member of Parliament for Wyre Forest. For Political and Public Service. Sandra Godley. For charitable service to the community in Coventry, West Midlands. Bruce Malcolm Gordon. Chair and Founder Member, Honorary Treasurers Forum.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.